Chemotherapy drugs act on actively dividing cells, including cancer cells and may damage normal tissues like bone marrow resulting in a reduced number of blood cells. The U.S. Food and Drug Administration (USFDA) recently approved trilaciclib for chemotherapy-induced bone marrow suppression in advanced-stage small-cell lung cancer patients. It may protect the bone marrow cells from chemotherapy-induced damage by inhibiting 4/6 cyclin-dependent kinase.
The drug approval would make chemotherapy safer and facilitate timely completion of scheduled treatment in patients with advanced-stage small-cell lung cancer. The efficacy of trilaciclib was evaluated in three randomized, double-blinded, placebo-controlled studies. A total of 245 patients with advanced-stage small-cell lung cancer were randomly assigned to receive trilaciclib or a placebo infusion, before chemotherapy. The presence and…
